


*Smole*  
Docket Number: 037003-0277847



*B*  
PATENT APPLICATION

Client Reference: 1998-30-0523VUS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

ANTONIO GRILLO-LOPEZ

Group Art Unit: 1642

Application No.: 09/762,587

Examiner: Minh Tam B. Davis

Filed: September 6, 2001

Confirmation No.: 5272

For: COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING  
ADMINISTRATION OF ANTI-CD20 ANTIBODY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed after submission of a request for continued examination and prior to mailing of a subsequent official action. No certification or fee is required.

Respectfully submitted,

A handwritten signature in black ink.

Thomas A. Cawley, Jr., Ph.D.  
Registration Number 40944

Date: April 26, 2004  
PILLSBURY WINTHROP LLP  
Telephone: (703) 905-2000  
Facsimile: (703) 905-2500  
P.O. Box 10500  
McLean, VA 22102  
TAC/JBM:ntb



FORM PTO-1449 (modified) (PW FORM PAT-1449)		Atty. Ref. No. 037003-0277847	Client Ref. No. 1998-30-0523VUS			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: GRILLO-LOPEZ				
		Appln. No.: 09/762,587				
		Filing Date: September 6, 2001				
Date: April 26, 2004		Page 1 of 2	Examiner: M.T.B. Davis			
U.S. PATENT DOCUMENTS						
Examiner Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)			
AR						
BR						
CR						
FOREIGN PATENT DOCUMENTS						
	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
DR						
ER						
FR						
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)						
GR	Chinn PC, et al., "Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma," <i>Int J Oncol</i> , 1999, 15:1017-25.					
HR	Chinn PC, et al., "IDE-C-Y2B8: a 90Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium," <i>Proc Am Assoc Cancer Res</i> , 1999, 40:574 (Abstract #3786).					
IR	Davis TA, et al., "90Ytrrium labeled anti-CD20 therapy for recurrent B-cell lymphoma," <i>Blood</i> , 1995, 86(10):273a (Abstract #1080).					
JR	Gordon LI, et al., "Zevalin™ (IDE-C-Y2B8) radioimmunotherapy of rituximab refractory follicular non-Hodgkin's lymphoma (NHL): interim results," <i>Blood</i> , 1999, 94(10):91a (Abstract #396).					
KR	Gordon LI, et al., "Update on IDE-C-YB8 (Zevalin™) radioimmunotherapy of B-cell NHL," <i>J Immunother</i> , 1999, 22(5) (Abstract #459).					
LR	Grillo-Lopez AT, et al., "Treatment (RX) of relapsed non-Hodgkin's lymphoma (NHL) using the 90-Yttrium (90Y) labeled anti-CD20 monoclonal antibody (MAB) IDE-C-Y2B8: a Phase I clinical trial (P1 CT)," <i>Ann Oncol</i> , 1996, 7(3 Suppl):57 (Abstract #195).					
MR	Grillo-Lopez AT, et al., "Phase I study of IDE-C-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma," <i>Blood</i> , 1995, 86(10):55a (Abstract #207).					
NR	Grillo-Lopez AT, et al., "Phase I and II studies in patients with non-Hodgkin's lymphoma," <i>Antibody Engineering</i> , 1994.					
OR	Knox SJ, et al., "90Y-anti-CD20 monoclonal antibody therapy for recurrent B-cell lymphoma," <i>Int J Radiat Oncol Biol Phys</i> , 1995, 32:215.					
PR	Knox SJ, et al., "90Y-anti-CD20 monoclonal antibody therapy (IDE-C-Y2B8) for recurrent B-cell lymphoma," <i>J Immunother</i> , 1994, 16(2):161 (Abstract #51).					
QR	Marquez SD, et al., "Hematological toxicity in radioimmunotherapy is predicted both by the computer absorbed whole body dose (cGy) and by the administered dose (mCi)," <i>Int J Radiat Oncol Biol Phys</i> , 1997, 39:327 (Abstract #2173).					
RR	White CA, et al., "Radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL): IDE-C-Y2B8 Phase I/II 90yttrium trial," <i>Ann Oncol</i> , 1999, 10(3 Suppl):64 (Abstract #215).					
SR	White CA, et al., "Zevalin™ radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma," <i>Eur J Cancer</i> , 1999, 35:S57 (Abstract #107).					

APR 26 2004  
TRADEMARK OFFICE

	TR	White CA, et al., "Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 9 anti-idiotype monoclonal antibodies," <i>Blood</i> , 1996, 87(9):3640-9.
	UR	Wiseman GA, et al., "Zevalin biodistribution and dosimetry estimated normal organ absorbed radiation doses are not affected by prior therapy with rituximab," <i>Blood</i> , 1999, 94(10):92a (Abstract #403).
	VR	Wiseman GA, et al., "Therapeutic index of IDEC-Y2B8 radioimmunotherapy: up to 850 fold greater radiation dose to tumor than to normal organs," <i>Proc Am Soc Clin Oncol</i> , 1999, 18(1 Suppl):4a (Abstract #13).
	WR	Wiseman GA, et al., "IDEC-Y2B8 (90yttrium ibritumomab tiuxetan) radioimmunotherapy safety results in relapsed or chemotherapy refractory non-Hodgkin's lymphoma (NHL) patients treated at reduced doses because of pre-existing thrombocytopenia," <i>Int J Radiat Oncol Biol Phys</i> , 1999, 45(3 Suppl):390 (Abstract #2217).
	XR	Wiseman GA, et al., "Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody," <i>Clin Cancer Res</i> , 1999, 5(Suppl):3281S-3286S.
	YR	Wiseman GA, et al., "Final dosimetry results of IDEC-Y2B8 Phase I/II 90Yttrium radioimmunotherapy trial in non-Hodgkin's lymphoma (NHL)," <i>J Nucl Med</i> , 1999, 40(10 Suppl):64P, (Abstract #260).
	ZR	Wiseman GA, et al., "90Yttrium labeled IDEC-Y2B8 anti-CD20 radioimmunotherapy of non-Hodgkin's lymphoma," <i>Cancer Biother Radiopharm</i> , 1999, 14(4):315 (Abstract #2).
	AAR	Wiseman GA, et al., "Non-Hodgkin's lymphoma tumor and bone marrow radiation doses from radioimmunotherapy with IDEC-Y2B8 yttrium-90 anti-CD20 monoclonal antibody," <i>J Nucl Med</i> , 1998, 39(5):69P (Abstract #267).
	BBR	Wiseman GA, et al., "Whole-body gamma camera image quantification from multiple camera types for radioisotope therapy dosimetry," <i>J Nucl Med</i> , 1998, 39(5 Suppl):185P (Abstract #836).
	CCR	Wiseman GA, et al., "IDEC-Y2B8 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim analysis," <i>Cancer Biother Radiopharm</i> , 1998, 13(4):317 (Abstract #51).
	DDR	Wiseman GA, et al., "Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 90Yttrium Radioimmunotherapy," <i>Proc Am Soc Clin</i> , 1998, (Abstract).
	EER	Wiseman GA, et al., "Radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8," <i>Int J Radiat Oncol Biol Phys</i> , 1998, 42(1 Suppl):130 (Abstract #11).
	FFR	Wiseman GA, et al., "Radioimmunotherapy relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 90 Yttrium anti-CD20 monoclonal," <i>Cancer Biother Radiopharm</i> , 1998, 13(1):59 (Abstract #22).
	GGR	Wiseman GA, et al., "IDEC-Y2B8 (90Y conjugated anti-CD20) dosimetry calculated from 111In anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM)," <i>Blood</i> , 1997, 90(10):510a (Abstract #2273).
	HHR	Wiseman GA, et al., "Y-90 anti-CD20 monoclonal antibody (IDEC-Y2B8) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma, <i>J Nucl Med</i> , 1997, 38(5 Suppl):251 (Abstract #1062).
	IIR	Witzig TE, et al., "Prospective randomized controlled study of Zevalin™ (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results," <i>Blood</i> , 1999, 94(10):631a (Abstract #2805).
	JJR	Witzig TE, et al., "Reduced-dose Zevalin™ radioimmunotherapy for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) patients with pre-existing thrombocytopenia: report of interim results of a Phase II trial," <i>Blood</i> , 1999, 94(10):92a (Abstract #400).
	KKR	Witzig TE, et al., "Commonly used response criteria for non-Hodgkin's lymphoma (NHL) applied to IDEC-Y2B8 radioimmunotherapy trial: importance of "normal" lymph node size," <i>Proc Am Soc Clin Oncol</i> , 1999, 18:41a (Abstract #152).
	LLR	Witzig TE, et al., "IDEC-Y2B8 radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma," <i>J Immunother</i> , 1998, 21(6):463.
	MMR	Witzig TE, et al., "IDEC-Y2B8 90yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim results of a Phase I/II trial," <i>Blood</i> , 1997, 90(10):586a (Abstract #2606).

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.